It is our firm belief that better outcomes are possible for patients with primary genetic immunodeficiencies and cancer. We strive everyday in our pursuit of new, innovative medicines that are designed to restore healthy immunity to treat disease.
Based upon the emerging science of immune regulation, our founders realized the potential of targeting CXCR4 as a validated pathway to stimulate healthy immunity in diseases.
X4 is advancing clinical studies with our pipeline of best-in-class, oral small molecule CXCR4-targeted medicines to treat rare primary immunodeficiency diseases and cancer.
August 02, 2017
X4 Pharmaceuticals Announces Rare Disease Research...
May 25, 2017
X4 Pharmaceuticals Announces Initiation of the Phase 2...